An­drew Rit­ter gath­ers the reins as his com­pa­ny preps PhI­II; Sol­id Bio co-founder Gi­lad Hay­eem re­tires

→ The se­ries of ex­ec­u­tive hir­ing at Rit­ter Phar­ma­ceu­ti­cals $RT­TR has cul­mi­nat­ed in co-founder An­drew Rit­ter’s ap­point­ment as CEO. Michael Step is step­ping down af­ter four years at the helm, but will con­tin­ue of­fer­ing guid­ance as a con­sul­tant and board di­rec­tor. This the com­pa­ny says, is all in prepa­ra­tion for the launch of a con­fir­ma­to­ry Phase III study that they hope would put their lac­tose in­tol­er­ance drug at the FDA’s door. In a Phase IIb/III study re­port­ed last year, the com­pa­ny was able to claim a win af­ter chang­ing the pri­ma­ry end­point and re­cal­cu­lat­ing the da­ta. With the tiny biotech’s fate rest­ing on the drug’s suc­cess (or not), Rit­ter, who now holds both the pres­i­dent and chief ex­ec­u­tive ti­tles and leads new col­leagues in­clud­ing CFO John Beck and R&D head Di­ane Plotkin, has big tasks ahead of him.  

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER